Browse the corpus

©2013 UpToDate ® Print Email Prognostic indices of survival for advanced mesothelioma in CALGB* studies CALGB studies Study Dates Response, percent MST, months #8435 (Mitomycin/cisplatin) 6/84-10/86 26 8.1 14 8.8 #8638 (Carboplatin) 2/87-2/88 7 7.1 #8833 (DHAC) 6/88-6/89 17 6.7 #8933 (Trimetrexate) 7/89-8/91 12 3.9 12 9.8 #9031 (DHAC/cisplatin) 7/90-7/93 14 6.4 #9131 (Edatrexate) 5/92-9/94 25 9.6 18 6.9 #9234 (Paclitaxel) 3/93-9/94 9 5 Poorprognostic factors in multivariate analysis Variable Relativerisk Pleural disease Present 2.64 Lactic dehydrogenase (LDH) >500 IU/L 1.91 Poor performance status (PS) PS1 1.65 PS2 2.71 Platelet count >400,000/microL 1.57 Epithelial histology Absent 1.33 Age Each yearover 75 yo 1.34 CALGBprognostic groups Group Characteristics MST, months Group I PS, 0; age<49 years 12.5 PS, 0; age ≥49 years; HGB* ≥14.6 14.5 Group II PS, 1or 2; WBC* < 8.7; no chest pain 9.5 Group III PS, 0; age>49 years; HGB <14.6 9.3 PS, 1 or 2; WBC < 15.6;chest pain; weight loss; HGB ≥12.3 9.3 PS, 1 or 2; 9.8 ≤ WBC< 15.6; chest pain; weight loss; HGB ≥ 11.2 9.6 Group IV PS, 1 or2; 8.7 ≤ WBC<15.6; no chest pain 6.6 Group V PS, 1 or 2; WBC<15.6;chest pain; no weight loss; HGB <12.3 3.9 PS, 1 or 2; 9.8 ≤ WBC <15.6; chestpain; weight loss; HGB <11.2 4.9 PS, 1 or 2; WBC< 9.8;chest pain; weight loss 3.9 Group VI PS, 1 or 2; WBC  ≥ 15.6 1.4 CALGB: cancer and leukemia Group B; MST: median survival time; Mos: months; DHAC: dihydro-5-azacytidine; WBC: white blood cell count, X 1000/microL; HGB: hemoglobin (HGB is given in g/percent; WBC, x 1000/microL).